iCAD Launches New VersaVue MR Software at RSNA 2012

  iCAD Launches New VersaVue MR Software at RSNA 2012

 Company to Showcase Latest Version of MR Image Analysis Suite Along with New
        PowerLook Advanced Mammography Platform for First Time at RSNA

RSNA 2012

Business Wire

CHICAGO -- November 25, 2012

iCAD, Inc.  (NASDAQ: ICAD),  an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the identification and
treatment of cancer, announced today it will launch VersaVue Enterprise 3.2.1,
the latest release of the company’s MR software solution that provides
improvements in workflow efficiency and flexibility, at the annual conference
of the Radiological Society of North America (RSNA) taking place in Chicago,
November 25-30.

“iCAD is committed to developing the most comprehensive, sophisticated image
analysis solutions to help clinicians increase efficiency and diagnostic
confidence,” said Ken Ferry, President and CEO of iCAD. “The new VersaVue
Enterprise solution will improve workflow and flexibility to aid clinical
decision making and treatment for patients, with an ultimate goal of
delivering improved patient care.”

VersaVue provides robust Dynamic Contrast Enhanced (DCE) MR image analysis and
flexible review and reporting tools that facilitate standardization of kinetic
analysis and interpretation and reporting of morphology. Using advanced thin
client architecture, VersaVue delivers real-time data access and eliminates
the need to purchase redundant hardware. The software features on-demand
viewing of studies anytime, anywhere to speed workflow as well as shared
knowledge of study status from a single, shared database. Unique features of
VersaVue Enterprise 3.2.1 include:

  *Fusion of ADC color overlays on any sequence
  *On the fly 3 time point calculation (Quick TP)
  *Fully automatic prostate segmentation of the capsule that will allow
    prostate volume reporting

VersaVue Enterprise is part of iCAD’s complete MRI product suite which
includes SpectraLook®, VividLook® and OmniLook®. These products offer
comprehensive quantitative image analysis for cancer detection, staging,
localization, treatment planning and serial monitoring.

iCAD will also be highlighting two prostate biopsy solutions at RSNA:

  *MRI Guided Prostate Biopsy (Currently pending FDA 510k clearance)

This solution will be a second generation system that will take advantage of
the MR scanners gradient fields along with an innovative biopsy needle
positioning device that is designed to provide radiologists with easier
patient set-up, reduce the number of scans to identify and calculate target
coordinates and reduce the total patient time in the magnet. The MRI guided
solution is a works in progress project.

  *MR TRUS Fusion for Prostate Biopsy

The current TRUS procedure has limitations in target hit rate and accuracy.
This next generation solution will improve target hit rate and accuracy, color
coding significant tracks by Gleason scores and storing those tracks to
compare for repeat biopsies particularly important for patients under active
surveillance. The system uses a unique organ based tracking technology using
3D end-fire ultrasound probe and elastic Fusion technology to fuse MR with US
images. MR TRUS Fusion is a solution that has product compatibility with the
VersaVue Enterprise MR solution. With VersaVue Enterprise 3.2.1 release there
will be expanded features that will be compatible with the MR TRUS Fusion
solution.

Additionally, iCAD’s workstation was used to process the MR images used in a
neuroradiology study that examined brain meningiomas. A scientific paper
presenting the study’s findings titled, “Intracranial Tumor Extravascular
Extracellular Space: Examining the Correlation Between ADC and DCE MRI Metrics
in Human Meningioma,” will be presented at RSNA on Tuesday, November 27 at
3:30 p.m. in room N226.

iCAD will also showcase its next generation computer-aided detection (CAD)
system for digital mammography, the PowerLook Advanced Mammography Platform
(AMP). The modular design of PowerLook AMP provides radiologists with the
ability to customize their CAD solution to meet the needs of their individual
work environment today and in the future. The technology expands on iCAD’s
SecondLook Digital solution and is the CAD platform upon which all future
breast imaging CAD offerings from iCAD will be built. PowerLook AMP’s CAD
metrics offer industry-leading tissue and lesion characteristics to support
the breast imager’s workflow. In addition, PowerLook AMP is the first product
of its kind to integrate Mātakina’s Volpara^® Volumetric Breast Density
assessment software that aids radiologists by standardizing their approach to
breast density assessment.

About iCAD, Inc.

iCAD is an industry-leading provider of Computer-Aided Detection (CAD)
technologies, advanced image analysis, workflow solutions and radiation
therapies for the early identification and treatment of common cancers. iCAD
offers a comprehensive range of high-performance, upgradeable CAD solutions
for mammography and advanced image analysis and workflow solutions for
Magnetic Resonance Imaging, for breast and prostate cancers and Computed
Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation
treatment for early-stage breast cancer that can be administered in the form
of intraoperative radiation therapy or accelerated partial breast irradiation.
The Xoft System is also cleared for the treatment of non-melanoma skin cancer
and endometrial cancer. For more information, call (877) iCADnow, or visit
www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995:

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
risks of uncertainty of patent protection, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible
technological obsolescence, increased competition, customer concentration and
other risks detailed in the Company’s filings with the Securities and Exchange
Commission. The words “believe”, “demonstrate”, “intend”, “expect”,
“estimate”, “anticipate”, “likely”, and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release.

Contact:

iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
For iCAD investor relations
LHA
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For iCAD media inquiries
Schwartz MSL
Helen Shik, 781-684-0770
iCAD@schwartzmsl.com
 
Press spacebar to pause and continue. Press esc to stop.